- ►endojournals.org PL Brubaker, DJ Drucker - Endocrinology, 2004 - Endocrine Soc Gut peptides exert diverse effects regulating satiety, gastrointestinal motility
and acid secretion, epithelial integrity, and both nutrient absorption and
disposal. These actions are initiated by activation of specific G protein- ... Cited by 216 - Related articles - BL Direct - All 7 versions
- ►endojournals.org L Farilla, A Bulotta, B Hirshberg, S Li Calzi, … - Endocrinology, 2003 - Endocrine Soc The peptide hormone, glucagon-like peptide 1 (GLP-1), has been shown to increase
glucose-dependent insulin secretion, enhance insulin gene transcription, expand
islet cell mass, and inhibit ß-cell apoptosis in animal models of ... Cited by 217 - Related articles - BL Direct - All 5 versions
- ►nih.gov M Prentki, CJ Nolan - Journal of Clinical Investigation, 2006 - Am Soc Clin Investig The major focus of this Review is on the mechanisms of islet β cell failure in
the pathogenesis of obesity-associated type 2 diabetes (T2D). As this demise
occurs within the context of β cell compensation for insulin resistance, ... Cited by 196 - Related articles - BL Direct - All 7 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion,
biological actions, and therapeutic relevance of the incretin peptides
glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like ... Cited by 173 - Related articles - All 25 versions
- ►diabetesjournals.org GG Holz - Diabetes, 2004 - Am Diabetes Assoc Recently published studies of islet cell function reveal unexpected features of
glucagon-like peptide-1 (GLP-1) receptor-mediated signal transduction in the
pancreatic β-cell. Although GLP-1 is established to be a cAMP-elevating ... Cited by 127 - Related articles - BL Direct - All 6 versions
- ►physiology.org L Bouwens, I Rooman - Physiological reviews, 2005 - Am Physiological Soc Beta-cell mass regulation represents a critical issue for understanding
diabetes, a disease characterized by a near-absolute (type 1) or relative (type
2) deficiency in the number of pancreatic beta cells. The number of islet ... Cited by 115 - Related articles - BL Direct - All 6 versions
J Buteau, W El-Assaad, CJ Rhodes, L … - Diabetologia, 2004 - Springer Aims/hypothesis. We have provided evidence that gluca- gon-like peptide-1, a
potential therapeutic agent in the treatment of diabetes, activates
phosphatidylinositol-3 kinase/protein kinase B signalling in the pancreatic ... Cited by 113 - Related articles - BL Direct - All 4 versions
- ►endojournals.org DJ Drucker - Endocrinology, 2003 - Endocrine Soc Studies of the natural history of type 2 diabetes inform us that a progressive
decline in ß-cell function is common in diabetic patients independent of the
method of treatment (2). Hence, new approaches are clearly needed that not ... Cited by 101 - Related articles - BL Direct - All 4 versions
Q Wang, L Li, E Xu, V Wong, C Rhodes, PL … - Diabetologia, 2004 - Springer Aims/hypothesis. The incretin hormone glucagon-like peptide-1 augments islet
cell mass in vivo by increas- ing proliferation and decreasing apoptosis of the
beta cells. However, the signalling pathways that mediate these effects are ... Cited by 94 - Related articles - BL Direct - All 4 versions
- ►tufts.edu [PDF] LL Baggio, DJ Drucker, 2006 - Annual Reviews Type 2 diabetes is characterized by hyperglycemia resulting from insulin
resistance in the setting of inadequate β-cell compensation. Currently
available therapeutic agents lower blood glucose through multiple ... Cited by 77 - Related articles - BL Direct - All 10 versions
